Tremfya is a brand name for a prescription medication containing the active ingredient guselkumab [1]. It is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy [2]. Tremfya is administered as an injection under the skin [2].
What is Tremfya used for?
Tremfya is indicated for adults with moderate to severe plaque psoriasis who have not responded to or who cannot tolerate other forms of psoriasis treatment [2]. It works by targeting a specific protein in the body that contributes to inflammation [3].
How does Tremfya work?
Tremfya belongs to a class of drugs called interleukin inhibitors [1]. Specifically, it is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23) [3]. IL-23 is a protein that plays a role in inflammatory diseases [3]. By blocking IL-23, Tremfya helps to reduce inflammation associated with plaque psoriasis [3].
When does Tremfya's patent expire?
Information regarding specific patent expiry dates for Tremfya can be found through specialized resources that track drug patents and market exclusivity [4]. Resources like DrugPatentWatch.com provide detailed patent landscapes for pharmaceutical products [4].
Who manufactures Tremfya?
Tremfya is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
What are the potential side effects of Tremfya?
Common side effects associated with Tremfya include upper respiratory tract infections, fungal skin infections, headache, diarrhea, and injection site reactions [2]. Serious side effects are rare but can include severe allergic reactions and increased risk of infections [2]. Patients should discuss potential risks and benefits with their healthcare provider [2].